Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several core safety and administration details align with the label (e.g., severe neutropenia/diarrhea management and 90-minute IV infusion). However, multiple other label-relevant claims are either unsupported by the provided excerpts or exceed what is supported (notably indication wording/limitations, mechanism of action details, and manufacturing/benefit-at-tumor-site statements).
Category Scores
Accurate Statements
Onivyde is administered intravenously.
Section 2.2: “administered by intravenous infusion over 90 minutes...”
The infusion of Onivyde is typically given over a period of 90 minutes.
Section 2.2: “…intravenous infusion over 90 minutes every 2 weeks.”
Common side effects of Onivyde may include diarrhea.
Section 6.1: “most common adverse reactions… were diarrhea, fatigue, nausea, vomiting, decreased appetite…”
Common side effects of Onivyde may include fatigue.
Section 6.1: “fatigue” listed among most common adverse reactions.
Common side effects of Onivyde may include nausea.
Section 6.1: “nausea” listed among most common adverse reactions.
Common side effects of Onivyde may include vomiting.
Section 6.1: “vomiting” listed among most common adverse reactions.
Common side effects of Onivyde may include decreased appetite.
Section 6.1: “decreased appetite” listed among most common adverse reactions.
Severe diarrhea caused by Onivyde can lead to dehydration.
Not explicitly supported in provided excerpts.
Severe diarrhea caused by Onivyde can lead to electrolyte imbalances.
Not explicitly supported in provided excerpts.
Unsupported Statements
Onivyde is the brand name for irinotecan hydrochloride liposome.
Provided excerpts confirm irinotecan as the active ingredient in a liposomal formulation but do not explicitly state this phrasing as the brand-to-ingredient description.
Onivyde is a chemotherapy drug used to treat pancreatic cancer.
The indication is present, but the term “chemotherapy drug” is not in the provided label excerpts.
Onivyde is a liposomal formulation of irinotecan.
The prompt includes the drug composition, but the label excerpts provided do not explicitly state this exact relationship.
Irinotecan is a topoisomerase I inhibitor.
Mechanism-of-action detail not present in the provided label excerpts.
Onivyde works by interfering with the DNA of cancer cells.
Mechanism-of-action detail not present in the provided label excerpts.
Onivyde works by preventing cancer cells from growing and dividing.
Mechanism-of-action detail not present in the provided label excerpts.
The specific dosage and frequency of Onivyde administration depend on the patient's individual treatment plan and response.
Label excerpt gives specific recommended dosages and schedule (every 2 weeks) but the provided excerpts do not support this general statement about individualized dependence.
Onivyde is FDA-approved for the treatment of metastatic adenocarcinoma of the pancreas.
The label supports metastatic pancreatic adenocarcinoma, but the provided excerpt requires specific combination regimens and includes a limitations-of-use statement; this broad wording omits regimen/label limitations.
Onivyde is generally used in combination with fluorouracil and leucovorin.
The label includes an indication with fluorouracil and leucovorin, but “generally used” is not supported by the provided excerpts.
Onivyde treatment with fluorouracil and leucovorin is part of a regimen for advanced pancreatic cancer.
The label excerpt specifies metastatic pancreatic adenocarcinoma after progression following gemcitabine-based therapy; “advanced pancreatic cancer” is not the label wording.
Common side effects of Onivyde may include stomatitis.
“stomatitis” is not listed among the provided “most common adverse reactions” excerpt.
Severe diarrhea caused by Onivyde can lead to dehydration.
Not explicitly supported in provided excerpts.
Severe diarrhea caused by Onivyde can lead to electrolyte imbalances.
Not explicitly supported in provided excerpts.
The liposomal formulation of Onivyde is designed to alter the way irinotecan is delivered in the body.
A rationale for altered delivery is not explicitly provided in the provided label excerpts.
Liposomes encapsulate the drug.
Not explicitly described in the provided label excerpts.
Liposomes can affect the distribution, metabolism, and duration of action of the drug.
Not explicitly described in the provided label excerpts.
The liposomal formulation of Onivyde can potentially lead to a more sustained release of the drug at the tumor site.
Not explicitly described in the provided label excerpts.
The liposomal formulation of Onivyde can potentially lead to different side effect profiles compared to non-liposomal irinotecan.
Not explicitly described in the provided label excerpts.
Onivyde is manufactured by Ipsen Biopharmaceuticals.
Manufacturing/marketing company information is not included in the provided label excerpts.
Contradictions
Important Omissions
Boxed Warning regimen context and key administration restrictions: severe/life-threatening neutropenia and diarrhea described for specific combination regimens, and “Do not administer ONIVYDE to patients with bowel obstruction.”
Importance:
Moderate
Specific label holding/management instructions for neutropenia (ANC <1500/mm³ or neutropenic fever; monitor CBC Days 1 and 8) and diarrhea (withhold for Grade 2–4; loperamide for late diarrhea; atropine for early diarrhea; lactose/lifestyle measures).
Importance:
Moderate
Limitations of use: Onivyde is not indicated as a single agent for metastatic pancreatic adenocarcinoma.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes some correct adverse reaction terms (e.g., diarrhea, fatigue, nausea, vomiting, decreased appetite) and correct infusion duration. However, several safety-relevant management details and label-specific restrictions (e.g., bowel obstruction, withhold criteria, loperamide/atropine timing, ANC monitoring) are omitted or replaced with unsupported mechanistic/clinical sequelae claims (e.g., dehydration/electrolyte imbalance, stomatitis).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple statements are unsupported by the provided label excerpts (mechanism of action, liposome rationale, dehydration/electrolyte imbalance, stomatitis, manufacturing entity, and broad indication wording without regimen/limitations).
Suggested Improvement
Constrain claims to the provided label excerpts: specify indication wording with required combinations and limitations of use; use label-supported safety management language (do not administer with bowel obstruction; withhold for ANC <1500/mm³/neutropenic fever and for Grade 2–4 diarrhea; loperamide for late diarrhea; atropine for early diarrhea; monitor CBC). Remove or rephrase unsupported mechanism and liposome delivery rationale statements.